Cytokinetics, Inc. (NASDAQ:CYTK) stock gained by 2.86%


Dallas, Texas 07/10/2013 (Financialstrend) – The shares of Cytokinetics, Inc. (NASDAQ:CYTK) are currently trading at $13.30, up by 2.86%. The stock opened at $12.89.

There was a noticeable fall in the price of the stock of Cytokinetics, Inc. (NASDAQ:CYTK) subsequent to the news that outcomes from a research of medicine for Lou Gehrig’s disease, also known as amyotrophiclateral sclerosis, may be deferred following the instance that fifty eight patients were given placebos by mistake. Afterwards, the losses were trimmed by the company after mentioning that steps have been taken to avert further erroneous study of drug assignments. Cytokinetics, Inc. (NASDAQ:CYTK) also specified that the error pertaining to the electronic data capture system programming was corrected.

A biopharmaceutical company, Cytokinetics, Inc. (NASDAQ:CYTK), has its entire focus on the finding and improvement of therapeutics of small molecule which adjusts function of muscle for the possible healing of the grave ailments and medical state of affairs. The research and development programs of the Cytokinetics, Inc. (NASDAQ:CYTK) that relate to the muscle function biology are aimed at modulators of small molecule of the cardiac contractility, smooth and skeletal muscle. The program – cardiac muscle contractility has its focus on cardiac sarcomere which is the heart’s fundamental muscle contraction unit. The primary candidate of drug of Cytokinetics, Inc. (NASDAQ:CYTK), CK-2017357 is Phase IIa clinical trials program’s subject. Another drug, CK-2017357 effectively treats medical conditions or diseases connected with wasting or weakness of the skeletal muscle. CK-2017357 obtained designation of an orphan drug in March 2010 for the amyotrophic lateral sclerosis’s treatment from the FDA.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.